kasA Resolved · high auto-curated

H37Rv Rv2245 · MTBC0 mtbc0_002387 · 416 aa · 2544273–2545523 MTBC0 (+) · RefSeq NP_216761.1

Genomic neighbourhood (genome browser)

Open in full genome browser →

This gene (outlined) in its genomic context; arrows are neighbouring genes coloured by verdict. Click any gene to navigate. Pan and zoom in the full browser.

Annotation: from legacy to revised

Legacy (H37Rv / Mycobrowser)3-oxoacyl-ACP synthase 1
MTBC0 PGAP re-annotation3-oxoacyl-ACP synthase KasA
Revised (this work)3-oxoacyl-ACP synthase KasA. Pfam: ketoacyl-synt (PF00109.33), Thiolase_N (PF00108.30), Ketoacyl-synt_C (PF02801.29).
Functional category (TubercuList)lipid metabolism

Auto-curated: this verdict and function were generated by rules from PGAP + Pfam + Foldseek and have not been hand-reviewed.

In the literature (TB corpus sweep) 128 publications

128 TB publications mention this gene. 128 publications discuss this gene. Queried separately, 119 records carry a M. tuberculosis context and 18 a non-TB mycobacterial context (species named in the 18-record verified sample: M. smegmatis (16), M. marinum (2)). The three counts come from three distinct PubMed queries (each with its own context filter), so they neither partition the total nor need to add up to it.

5 of 128: the most recently indexed records of the curated sweep at its date, not necessarily the most recent papers on this gene — the exhaustive list below is later and broader and may hold newer ones.
PublicationDate
Anti-mycobacterial activity of phytocompounds from Ricinus communis L. - an integrated in-vitro and in-silico approach. doi:10.1080/07391102.2026.2695928 2026
Targeting KasA: isosakuranetin derivatives as promising scaffolds for novel anti-tuberculosis agents against drug-resistant Mycobacterium tuberculosis. doi:10.3389/fbinf.2026.1777858 2026
In Vitro and In Silico Approaches for the Evaluation of Antimycobacterial and Biofilm Inhibition Activity of Asiatic Acid Against Dual Targets of Mycobacterium smegmatis. doi:10.2174/0115680266395445251204125654 2026
Halting Tuberculosis in Its Tracks: Advances and Strategies for Discovering Therapeutic Targets in Mycobacterium tuberculosis. doi:10.1002/ddr.70239 2026
Protein-Mediated Virulence in Mycobacterium tuberculosis. doi:10.1007/978-3-031-96883-9_5 2026
133 records returned by the alias sweep (a separate sweep from the 128 above; both are shown, neither is exhaustive)

Searched as: Rv2245, kasA, Mb2269, ML1655, MMAR_3338, MSMEG_4327, MAB_1877c — each in conjunction with a mycobacterial context term. Swept 2026-09-07.

PublicationJournalYear
Free energy perturbation and machine learning-assisted identification of novel molecules for the Mycobacterium tuberculosis KasA protein: a fragment-based drug design approach. doi:10.1007/s11030-026-11726-9 names it Mol Divers 2026
Anti-mycobacterial activity of phytocompounds from Ricinus communis L. - an integrated in-vitro and in-silico approach. doi:10.1080/07391102.2026.2695928 J Biomol Struct Dyn 2026
Targeting KasA: isosakuranetin derivatives as promising scaffolds for novel anti-tuberculosis agents against drug-resistant Mycobacterium tuberculosis. doi:10.3389/fbinf.2026.1777858 names it Front Bioinform 2026
In Vitro and In Silico Approaches for the Evaluation of Antimycobacterial and Biofilm Inhibition Activity of Asiatic Acid Against Dual Targets of Mycobacterium smegmatis. doi:10.2174/0115680266395445251204125654 Curr Top Med Chem 2026
Halting Tuberculosis in Its Tracks: Advances and Strategies for Discovering Therapeutic Targets in Mycobacterium tuberculosis. doi:10.1002/ddr.70239 Drug Dev Res 2026
Protein-Mediated Virulence in Mycobacterium tuberculosis. doi:10.1007/978-3-031-96883-9_5 Adv Exp Med Biol 2026
Mycobacterium tuberculosis FAS-II pathway targeted integrative deep learning based identification of potential anti-tubercular agents. doi:10.1007/s10822-025-00695-0 J Comput Aided Mol Des 2025
Targeting Mycolic Acid Biosynthesis with Cyclic Sulfamates: A New Strategy against Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.5c00419 ACS Infect Dis 2025
Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. doi:10.1016/j.jacc.2025.08.015 J Am Coll Cardiol 2025
Synthesis and Biological Evaluation of Platensimycin Analogues with Improved Antimycobacterial Activity. doi:10.1021/acs.jmedchem.5c01856 J Med Chem 2025
A computational approach to mycolic acid biosynthesis disruption in mycobacterium tuberculosis via molluscan metabolites as KasA inhibitors. doi:10.1038/s41598-025-13329-0 names it Sci Rep 2025
The KasA inhibitor JSF-3285 improves the sterilizing activity of bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosis. doi:10.1128/aac.00130-25 names it Antimicrob Agents Chemother 2025
Identification of Antituberculars with Favorable Potency and Pharmacokinetics through Structure-Based and Ligand-Based Modeling. doi:10.1101/2025.02.03.636334 bioRxiv 2025
New thiazolyl-isoxazole derivatives as potential anti-infective agents: design, synthesis, in vitro and in silico antimicrobial efficacy. doi:10.1080/07391102.2024.2306497 J Biomol Struct Dyn 2025
Virtual screening and identification of promising therapeutic compounds against drug-resistant Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein synthase I (KasA). doi:10.1080/07391102.2023.2293276 names it J Biomol Struct Dyn 2025
Identification of potent indolizine derivatives against Mycobacterial tuberculosis: In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies. doi:10.1016/j.ijbiomac.2024.133285 Int J Biol Macromol 2024
Synthesis, Molecular Docking, Molecular Dynamic Simulation Studies, and Antitubercular Activity Evaluation of Substituted Benzimidazole Derivatives. doi:10.1155/2024/9986613 Adv Pharmacol Pharm Sci 2024
Mechanistic Insight into how β-Ketoacyl ACP Synthase I (KasA) Recognizes the Fatty Acid Chain Length of its Substrate. doi:10.1002/cplu.202300568 names it Chempluschem 2024
Computational evaluation of marine demospongiae sponges metabolites activity as mycolic acid biosynthesis inhibitors in Mycobacterium tuberculosis. doi:10.4103/ijmy.ijmy_149_23 Int J Mycobacteriol 2023
In vitro and in silico evaluations of actinomycin X(2)and actinomycin D as potent anti-tuberculosis agents. doi:10.7717/peerj.14502 PeerJ 2023
Probing into the Flap-dimer Dynamics of the Mycobacterium tuberculosis Kasa Enzyme Binding Landscape Provides the Underlying Inhibitory Mechanisms of JSF-3285 and 5G. doi:10.2174/1568026623666230125124433 names it Curr Top Med Chem 2023
Mycobacterium tuberculosis KasA as a drug target: Structure-based inhibitor design. doi:10.3389/fcimb.2022.1008213 names it Front Cell Infect Microbiol 2022
Indole: A promising scaffold for the discovery and development of potential anti-tubercular agents. doi:10.1016/j.crphar.2022.100119 Curr Res Pharmacol Drug Discov 2022
Pyridine appended 2-hydrazinylthiazole derivatives: design, synthesis, in vitro and in silico antimycobacterial studies. doi:10.1039/d2ra02163c RSC Adv 2022
Localization of EccA(3) at the growing pole in Mycobacterium smegmatis. doi:10.1186/s12866-022-02554-6 BMC Microbiol 2022
Acetylene containing 2-(2-hydrazinyl)thiazole derivatives: design, synthesis, and in vitro and in silico evaluation of antimycobacterial activity against Mycobacterium tuberculosis. doi:10.1039/d2ra00928e RSC Adv 2022
Exploring the impact of biochar on antibiotics and antibiotics resistance genes in pig manure aerobic composting through untargeted metabolomics and metagenomics. doi:10.1016/j.biortech.2022.127118 Bioresour Technol 2022
Detection and characterization of mutations in genes related to isoniazid resistance in Mycobacterium tuberculosis clinical isolates from Iran. doi:10.1007/s11033-022-07404-2 Mol Biol Rep 2022
Progress in health among regions of Ethiopia, 1990-2019: a subnational country analysis for the Global Burden of Disease Study 2019. doi:10.1016/S0140-6736(21)02868-3 Lancet 2022
The whole-genome sequencing in predicting Mycobacterium tuberculosis drug susceptibility and resistance in Papua, Indonesia. doi:10.1186/s12864-021-08139-3 BMC Genomics 2021
Genomic characterization of variants on mycolic acid metabolism genes in Mycobacterium tuberculosis isolates from Santa Catarina, Southern Brazil. doi:10.1016/j.meegid.2021.105107 Infect Genet Evol 2021
Morphology, Anatomy and Secondary Metabolites Investigations of Premna odorata Blanco and Evaluation of Its Anti-Tuberculosis Activity Using In Vitro and In Silico Studies. doi:10.3390/plants10091953 Plants (Basel) 2021
Ligand-protein interactions of plant-isolated (9z,12z)-octadeca-9,12-dienoic acid with Β-ketoacyl-Acp synthase (KasA) in potential anti-tubercular drug designing. doi:10.1016/j.sciaf.2021.e00824 names it Sci Afr 2021
Genome analyses of 174 strains of Mycobacterium tuberculosis provide insight into the evolution of drug resistance and reveal potential drug targets. doi:10.1099/mgen.0.000542 Microb Genom 2021
Tuberculosis (TB) in the refugee camps in Ethiopia: trends of case notification, profile, and treatment outcomes, 2014 to 2017. doi:10.1186/s12879-021-05828-y BMC Infect Dis 2021
Molecular Docking Suggests the Targets of Anti-Mycobacterial Natural Products. doi:10.3390/molecules26020475 Molecules 2021
Quantitative structure-activity relationship (QSAR) and molecular docking of xanthone derivatives as anti-tuberculosis agents. doi:10.1016/j.jctube.2020.100203 J Clin Tuberc Other Mycobact Dis 2020
Computational Approaches to Identify Molecules Binding to Mycobacterium tuberculosis KasA. doi:10.1021/acsomega.0c04271 names it ACS Omega 2020
Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System. doi:10.1128/AAC.01914-20 Antimicrob Agents Chemother 2020
Acetylation of Isoniazid Is a Novel Mechanism of Isoniazid Resistance in Mycobacterium tuberculosis. doi:10.1128/AAC.00456-20 Antimicrob Agents Chemother 2020
Anti-Tubercular Properties of 4-Amino-5-(4-Fluoro-3- Phenoxyphenyl)-4H-1,2,4-Triazole-3-Thiol and Its Schiff Bases: Computational Input and Molecular Dynamics. doi:10.3390/antibiotics9090559 Antibiotics (Basel) 2020
Identifying isoniazid resistance markers to guide inclusion of high-dose isoniazid in tuberculosis treatment regimens. doi:10.1016/j.cmi.2020.07.004 Clin Microbiol Infect 2020
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening. doi:10.1016/j.ejmech.2020.112440 Eur J Med Chem 2020
(E)-2-(2-Allylidenehydrazinyl)thiazole derivatives: Design, green synthesis, in silico and in vitro antimycobacterial and radical scavenging studies. doi:10.1002/ardp.202000003 Arch Pharm (Weinheim) 2020
Indole chalcones: Design, synthesis, in vitro and in silico evaluation against Mycobacterium tuberculosis. doi:10.1016/j.ejmech.2020.112358 Eur J Med Chem 2020
Mutations in Mycobacterium tuberculosis Isolates with Discordant Results for Drug-Susceptibility Testing in Peru. doi:10.1155/2020/8253546 Int J Microbiol 2020
Transcriptional and Mycolic Acid Profiling in Mycobacterium bovis BCG In Vitro Show an Effect for c-di-GMP and Overlap between Dormancy and Biofilms. doi:10.4014/jmb.1911.11043 J Microbiol Biotechnol 2020
A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA. doi:10.1016/j.chembiol.2020.02.007 names it Cell Chem Biol 2020
Exploring the SAR of the β-Ketoacyl-ACP Synthase Inhibitor GSK3011724A and Optimization around a Genotoxic Metabolite. doi:10.1021/acsinfecdis.9b00493 ACS Infect Dis 2020
Structural insight into conformational dynamics of non-active site mutations in KasA: A Mycobacterium tuberculosis target protein. doi:10.1016/j.gene.2019.144082 names it Gene 2019
Knowledge, attitude and preventive practice towards tuberculosis among clients visiting public health facilities. doi:10.1186/s13104-019-4292-2 BMC Res Notes 2019
In Silico Study to Identify New Antituberculosis Molecules from Natural Sources by Hierarchical Virtual Screening and Molecular Dynamics Simulations. doi:10.3390/ph12010036 Pharmaceuticals (Basel) 2019
Kinase Targets for Mycolic Acid Biosynthesis in Mycobacterium tuberculosis. doi:10.2174/1874467211666181025141114 Curr Mol Pharmacol 2019
In Silico Drug Design of Thiolactomycin Derivatives Against Mtb-KasA Enzyme to Inhibit Multidrug Resistance of Mycobacterium tuberculosis. doi:10.1007/s12539-017-0257-0 names it Interdiscip Sci 2019
Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA. doi:10.1128/mBio.02101-17 names it mBio 2018
Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis. doi:10.1016/j.bioorg.2018.08.025 Bioorg Chem 2018
Design, Synthesis and Biological Evaluation of Some Triazole Schiff's Base Derivatives as Potential Antitubercular Agents. doi:10.2174/1874104501812010048 Open Med Chem J 2018
Interactome analysis of Rv0148 to predict potential targets and their pathways linked to aminoglycosides drug resistance: An insilico approach. doi:10.1016/j.micpath.2018.05.034 Microb Pathog 2018
Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. doi:10.1016/j.meegid.2016.09.004 Infect Genet Evol 2016
Identification of KasA as the cellular target of an anti-tubercular scaffold. doi:10.1038/ncomms12581 names it Nat Commun 2016
Clinical efficacy of Vyaghriharitaki Avaleha in the management of chronic bronchitis. doi:10.4103/0974-8520.169009 Ayu 2015
DOUBLE-STEP MULTIPLEX REAL TIME PCR WITH MELTING CURVE ANALYSIS FOR DETECTION AND DIFFERENTIATION OF MYCOBACTERIA IN SPUTUM. Southeast Asian J Trop Med Public Health 2015
Comparative metabolic profiling of mce1 operon mutant vs wild-type Mycobacterium tuberculosis strains. doi:10.1093/femspd/ftv066 Pathog Dis 2015
Mutation profiling for detection of isoniazid resistance in Mycobacterium tuberculosis clinical isolates. doi:10.1093/jac/dkv253 J Antimicrob Chemother 2015
Proteomic analysis of ofloxacin-mono resistant Mycobacterium tuberculosis isolates. doi:10.1016/j.jprot.2015.07.031 J Proteomics 2015
2-Aminothiazole derivatives as antimycobacterial agents: Synthesis, characterization, in vitro and in silico studies. doi:10.1016/j.ejmech.2014.09.086 Eur J Med Chem 2014
Detecting novel genetic variants associated with isoniazid-resistant Mycobacterium tuberculosis. doi:10.1371/journal.pone.0102383 PLoS One 2014
Detection of mutations associated with isoniazid resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates. doi:10.1093/jac/dku161 J Antimicrob Chemother 2014
Evidence of Clonal Expansion in the Genome of a Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolate from Peru. doi:10.1128/genomeA.00089-14 Genome Announc 2014
The protonation state of catalytic residues in the resting state of KasA revisited: detailed mechanism for the activation of KasA by its own substrate. doi:10.1021/bi401308j names it Biochemistry 2014
New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics. doi:10.2174/1381612819666131118203641 Curr Pharm Des 2014
Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. doi:10.1093/jac/dkt358 J Antimicrob Chemother 2014
Structural basis for the recognition of mycolic acid precursors by KasA, a condensing enzyme and drug target from Mycobacterium tuberculosis. doi:10.1074/jbc.M113.511436 names it J Biol Chem 2013
Clarification on the decarboxylation mechanism in KasA based on the protonation state of key residues in the acyl-enzyme state. doi:10.1021/jp403067m names it J Phys Chem B 2013
Regulation of lipid biosynthesis, sliding motility, and biofilm formation by a membrane-anchored nucleoid-associated protein of Mycobacterium tuberculosis. doi:10.1128/JB.02081-12 J Bacteriol 2013
Thiolactomycin-based β-ketoacyl-AcpM synthase A (KasA) inhibitors: fragment-based inhibitor discovery using transient one-dimensional nuclear overhauser effect NMR spectroscopy. doi:10.1074/jbc.M112.414516 names it J Biol Chem 2013
Rv3080c regulates the rate of inhibition of mycobacteria by isoniazid through FabD. doi:10.1007/s11010-012-1514-5 Mol Cell Biochem 2013
Diversion of phagosome trafficking by pathogenic Rhodococcus equi depends on mycolic acid chain length. doi:10.1111/cmi.12050 Cell Microbiol 2013
Clinical efficacy of Bhringarajasava as Naimittika Rasayana in Rajayakshma with special reference to pulmonary tuberculosis. doi:10.4103/0974-8520.110536 Ayu 2012
Insights into the distribution and functions of the eukaryotic GPI-like anchored genes among Mycobacterium from a comparative genomic perspective. doi:10.1615/critreveukargeneexpr.v22.i4.40 Crit Rev Eukaryot Gene Expr 2012
Molecular dynamics of Mycobacterium tuberculosis KasA: implications for inhibitor and substrate binding and consequences for drug design. doi:10.1007/s10822-011-9483-4 names it J Comput Aided Mol Des 2011
Substrate recognition by β-ketoacyl-ACP synthases. doi:10.1021/bi201199x Biochemistry 2011
Elucidation of the protonation states of the catalytic residues in mtKasA: implications for inhibitor design. doi:10.1021/bi200006t Biochemistry 2011
The β-ketoacyl-ACP synthase from Mycobacterium tuberculosis as potential drug targets. doi:10.2174/092986711795029636 Curr Med Chem 2011
M. tuberculosis intramembrane protease Rip1 controls transcription through three anti-sigma factor substrates. doi:10.1111/j.1365-2958.2010.07232.x Mol Microbiol 2010
Slow onset inhibition of bacterial beta-ketoacyl-acyl carrier protein synthases by thiolactomycin. doi:10.1074/jbc.M109.077909 J Biol Chem 2010
Physiological function of mycobacterial mtFabD, an essential malonyl-CoA:AcpM transacylase of type 2 fatty acid synthase FASII, in yeast mct1Delta cells. doi:10.1155/2009/836172 Comp Funct Genomics 2009
Platensimycin activity against mycobacterial beta-ketoacyl-ACP synthases. doi:10.1371/journal.pone.0006306 PLoS One 2009
Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin. doi:10.1016/j.str.2009.04.012 names it Structure 2009
KasA, another brick in the mycobacterial cell wall. doi:10.1016/j.str.2009.06.006 names it Structure 2009
Contribution of dfrA and inhA mutations to the detection of isoniazid-resistant Mycobacterium tuberculosis isolates. doi:10.1128/AAC.00433-09 Antimicrob Agents Chemother 2009
A novel interaction linking the FAS-II and phthiocerol dimycocerosate (PDIM) biosynthetic pathways. doi:10.1074/jbc.M802169200 J Biol Chem 2008
Function of heterologous Mycobacterium tuberculosis InhA, a type 2 fatty acid synthase enzyme involved in extending C20 fatty acids to C60-to-C90 mycolic acids, during de novo lipoic acid synthesis in Saccharomyces cerevisiae. doi:10.1128/AEM.00655-08 Appl Environ Microbiol 2008
Molecular analysis of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from India. doi:10.1016/j.ijantimicag.2007.08.013 Int J Antimicrob Agents 2008
Roles of SigB and SigF in the Mycobacterium tuberculosis sigma factor network. doi:10.1128/JB.01273-07 J Bacteriol 2008
The Mycobacterium tuberculosis FAS-II condensing enzymes: their role in mycolic acid biosynthesis, acid-fastness, pathogenesis and in future drug development. doi:10.1111/j.1365-2958.2007.05761.x Mol Microbiol 2007
Analysis of the role of Mycobacterium tuberculosis kasA gene mutations in isoniazid resistance. doi:10.1111/j.1469-0691.2007.01752.x names it Clin Microbiol Infect 2007
Mycobacterium tuberculosis SigM positively regulates Esx secreted protein and nonribosomal peptide synthetase genes and down regulates virulence-associated surface lipid synthesis. doi:10.1128/JB.01212-06 J Bacteriol 2006
The condensing activities of the Mycobacterium tuberculosis type II fatty acid synthase are differentially regulated by phosphorylation. doi:10.1074/jbc.M601691200 J Biol Chem 2006
Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. doi:10.1128/AAC.00112-06 Antimicrob Agents Chemother 2006
Quantitative proteomic analysis of drug-induced changes in mycobacteria. doi:10.1021/pr050248t J Proteome Res 2006
GroEL1: a dedicated chaperone involved in mycolic acid biosynthesis during biofilm formation in mycobacteria. doi:10.1016/j.cell.2005.09.012 Cell 2005
Detection of mutations associated with isoniazid resistance in Mycobacterium tuberculosis isolates from China. doi:10.1128/JCM.43.11.5477-5482.2005 J Clin Microbiol 2005
Conditional depletion of KasA, a key enzyme of mycolic acid biosynthesis, leads to mycobacterial cell lysis. doi:10.1128/JB.187.22.7596-7606.2005 names it J Bacteriol 2005
The biosynthesis of mycolic acids in Mycobacterium tuberculosis relies on multiple specialized elongation complexes interconnected by specific protein-protein interactions. doi:10.1016/j.jmb.2005.09.016 J Mol Biol 2005
[The characteristics of the sensitivity of Mycobacterium tuberculosis to rifampicin and isoniazid through determination of mutations in the genes rpoB, katG, inhA, oxyR, and kasA by different molecular biological assays]. names it Probl Tuberk Bolezn Legk 2005
[Characterization of the katG, inhA, ahpC, kasA, and oxyR gene mutations in isoniazid-resistant and susceptible strain of Mycobacterium tuberculosis by automated DNA sequencing]. names it Zhonghua Jie He He Hu Xi Za Zhi 2005
Mutations responsible for Mycobacterium tuberculosis isoniazid resistance in Italy. Int J Tuberc Lung Dis 2005
Protein-protein interactions within the Fatty Acid Synthase-II system of Mycobacterium tuberculosis are essential for mycobacterial viability. doi:10.1111/j.1365-2958.2004.04334.x Mol Microbiol 2004
Development of a scintillation proximity assay for the Mycobacterium tuberculosis KasA and KasB enzymes involved in mycolic acid biosynthesis. doi:10.1016/j.tube.2004.03.001 names it Tuberculosis (Edinb) 2004
Induction of Mycobacterium avium proteins upon infection of human macrophages. doi:10.1002/pmic.200300891 Proteomics 2004
Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil. doi:10.1128/AAC.48.9.3373-3381.2004 Antimicrob Agents Chemother 2004
[New technologies in the determination of drug susceptibility in Mycobacterium tuberculosis]. Probl Tuberk Bolezn Legk 2004
Requirement for kasB in Mycobacterium mycolic acid biosynthesis, cell wall impermeability and intracellular survival: implications for therapy. doi:10.1046/j.1365-2958.2003.03667.x Mol Microbiol 2003
Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis. doi:10.1128/AAC.47.9.2903-2913.2003 Antimicrob Agents Chemother 2003
Modeling bacterial evolution with comparative-genome-based marker systems: application to Mycobacterium tuberculosis evolution and pathogenesis. doi:10.1128/JB.185.11.3392-3399.2003 J Bacteriol 2003
Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. doi:10.1074/jbc.M302435200 names it J Biol Chem 2003
Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. doi:10.1128/AAC.47.4.1241-1250.2003 Antimicrob Agents Chemother 2003
The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis. doi:10.1054/tube.2002.0333 names it Tuberculosis (Edinb) 2002
Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. doi:10.1046/j.1365-2958.2002.03162.x names it Mol Microbiol 2002
In situ detection of Mycobacterium tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions. doi:10.1128/IAI.70.11.6330-6338.2002 Infect Immun 2002
Temperature-induced changes in the cell-wall components of Mycobacterium thermoresistibile. doi:10.1099/00221287-148-10-3145 Microbiology (Reading) 2002
Mycolic acid biosynthesis and enzymic characterization of the beta-ketoacyl-ACP synthase A-condensing enzyme from Mycobacterium tuberculosis. doi:10.1042/BJ20011628 Biochem J 2002
Purification and biochemical characterization of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases KasA and KasB. doi:10.1074/jbc.M108903200 names it J Biol Chem 2001
Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. doi:10.1128/AAC.45.7.2157-2159.2001 Antimicrob Agents Chemother 2001
Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. doi:10.1046/j.1365-2958.2000.02145.x Mol Microbiol 2000
Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. doi:10.1128/JB.182.14.4059-4067.2000 J Bacteriol 2000
Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. doi:10.1074/jbc.M000569200 names it J Biol Chem 2000
Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. doi:10.1128/AAC.44.1.103-110.2000 Antimicrob Agents Chemother 2000
Detection of mutations in drug resistance genes of Mycobacterium tuberculosis by a dot-blot hybridization strategy. doi:10.1054/tuld.1999.0222 Tuber Lung Dis 1999
Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. doi:10.1128/AAC.43.8.2087 names it Antimicrob Agents Chemother 1999
Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. doi:10.1054/tuld.1998.0002 Tuber Lung Dis 1998
Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. doi:10.1126/science.280.5369.1607 Science 1998

Title+abstract index only: a paper that names this gene solely in its body text, a figure legend or a supplement is invisible here. That is why this list sits beside the curated layer rather than replacing it - Rv0007's characterisation, found by a full-text sweep, returns zero in this one. Absence from this list is not absence from the literature. Source: PubMed E-utilities sweep (esearch + esummary), every alias of the gene searched in conjunction with a mycobacterial context term; ambiguous common-word aliases excluded. phase198, 2026-09-06.

This layer CITES the literature and adds context; it does not change the verdict or the function stated elsewhere in this fiche. This distinguishes a gene that is dark because nobody has looked from one that is dark despite having been studied. Source: PubMed (whole): H37Rv locus tag + GENE NAME + ortholog identifiers (Mb…, MMAR_…, MSMEG_…, ML…, MAB_…), under a mycobacterial context filter; hits verified against the abstract text. Species-context counts distinguish M. tuberculosis literature from literature on other mycobacteria. phase76/phase77, 2026-07-13.

Genomic-neighbour overlap (structural caveat) co-directional · 0 % of gene

NeighbouracpP (Rv2244, + strand)
Overlap4 bp, 0 % of this gene's length

co-directional overlap: ordinary (e.g. shared stop/start codons in an operon), not the Rv2438A-type artefact P20.1, derived from GFF3 gene coordinates, 2026-08-03.

Conditional expression context (iModulons)

Member of 1 independently-modulated gene set(s): Fatty Acid Biosynthesis (trcR and Rv1776c and whiB4 ).

iModulon membership (independently-modulated gene sets from a 647-sample RNA-seq compendium): the conditional co-expression context. Co-expression is a regulatory context, NOT a molecular function. Source: iModulonDB / modulome_mtb (Yoo 2022).

CRISPRi vulnerability

Vulnerability index -12.69 (95% CI -13.84 to -11.64). A more negative index = more vulnerable to knockdown (better drug-target quality); indicative threshold VI ≤ -6 = highly vulnerable.

Quantitative CRISPRi knockdown, graded (finer than binary Tn-seq essentiality). Source: CRISPRi vulnerability index (Bosch 2021, supplementary Table S2 'mmc3.xlsx', bulk import via Europe PMC -- supersedes the per-gene pebble.rockefeller.edu scrape of phase46_crispri_vulnerability.py).

Legacy record & comparison (Mycobrowser)

Mycobrowser functionInvolved in fatty acid biosynthesis (mycolic acids synthesis); involved in meromycolate extension. Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP [catalytic activity: acyl-[acyl-carrier protein] + malonyl-[acyl-carrier protein] = 3-oxoacyl-[acyl-carrier protein] + [acyl-carrier protein] + CO(2)].
Mycobrowser EC 2.3.1.41 · superseded EC numbering; the atlas uses the current class (2.3.1.179, 2.3.1.293)

The legacy Mycobrowser record is shown for verification. Mycobrowser is no longer maintained; its EC numbers predate recent nomenclature revisions, so a class change usually reflects re-numbering, not a conflict.

Orthologues (reciprocal best hits across mycobacteria)

M. bovis Mb2269 · 100.0% identity
M. leprae ML1655 · 92.8% identity
M. marinum MMAR_3338 · 92.5% identity
M. smegmatis MSMEG_4327 · 86.3% identity
M. orygis RJtmp_002321 · 100.0% identity
M. abscessus MAB_1877c · 80.0% identity

Reciprocal-best-hit orthologues (DIAMOND) against the Mycobrowser reference proteomes. A missing species is informative: e.g. a gene absent from M. leprae was likely lost in its reductive genome evolution. Locus tags link to Mycobrowser.

Curated reference (UniProt)

UniProt P9WQD9 SwissProt · reviewed · Evidence at protein level
UniProt name3-oxoacyl-[acyl-carrier-protein] synthase 1
EC (curated) EC 2.3.1.293
Curated functionPart of the mycobacterial fatty acid elongation system FAS-II, which is involved in mycolic acid biosynthesis. Catalyzes the elongation of long chain acyl-ACP substrates by the addition of two carbons from malonyl-ACP to an acyl acceptor. Involved in the initial extension of the mycolate chain and forms monounsaturated fatty acids that averaged 40 carbons in length.

Functional vocabulary (eggNOG-mapper, orthology transfer)

COG category I Lipid transport and metabolism
Q Secondary metabolites biosynthesis, transport and catabolism
Preferred namekasA
eggNOG descriptionBelongs to the beta-ketoacyl-ACP synthases family
Orthologous groupCOG0304
EC number EC 2.3.1.179
KEGG orthology K09458, K11609
KEGG pathways map00061, map00780, map01100, map01212
KEGG modules M00083, M00572
Gene Ontology (49) GO:0003674, GO:0003824, GO:0004312, GO:0004315, GO:0005488, GO:0005515, GO:0005575, GO:0005618, GO:0005622, GO:0005623, GO:0005737, GO:0005829 +37 more

Orthology-based transfer (eggNOG 5.0.2, diamond). EC/KO/GO/CAZy are computed annotations, not manual curation; cross-check against the primary literature before treating a specific reaction as established.

Conservation & selection (intra-MTBC, 142 601 strains, snapshot of 2026-09-29)

pN/pS 0.172 · strong purifying
Polymorphic sites (≥ 0.1% of strains) 6 synonymous, 3 missense, 0 nonsense, 0 frameshift

pN/pS from segregating SNPs (singletons removed) normalised by possible sites. Low pN/pS = purifying selection (a strong signal that a "hypothetical" is a real, constrained gene). A high pN/pS is ambiguous: relaxed constraint or positive selection (drug resistance, antigenic variation) inflate it; e.g. rpoB/katG/pncA score high here for resistance, not loss of function. A clonal disruption (one allele over a clade) suggests lineage pseudogenisation; a convergent one (many independent alleles) is typical of resistance loss-of-function.

Outgroup conservation (beyond the MTBC) Bacteria

M. canettii dN/dS (deep-divergence selection) 0.0 (low power) · 2 consensus substitution(s)
low power (2 canettii-consensus substitution(s)); present in M. canettii but dN/dS not reliable
Limitation: dN/dS mixes fixed canettii-H37Rv divergence with intra-canettii polymorphism, and is not polarised (the per-gene repolarisation is not viable: 79 % of the consensus SPDI lie outside the polarised table).
Genus-wide presence (~53 non-MTBC Mycobacterium) present in 53/53 (100%) · mean identity 91.3% · 4/4 closest MTBAP relatives
conserved across the genus (present in 53/53 non-MTBC Mycobacterium genomes, incl. distant relatives) — an ancient core gene predating the genus radiation
Phylostratum (deepest detected homolog) MTBC-specific → Mycobacterium → Mycobacteriaceae → Corynebacteriales → Actinomycetia → Bacteria
detected in 10/13 non-Mycobacterium reference genomes (down to Bacteria) · mean identity 56.6%
detected down to outside the phylum (Proteobacteria/Firmicutes controls) — a universally conserved, ancient bacterial gene

Two orthogonal outgroup signals. M. canettii (the immediate outgroup) gives a deep-divergence dN/dS (a low value confirms a constrained, real gene; shown as confident only at ≥8 substitutions, else flagged low-power). Genus-wide presence/absence (tblastn vs assembled non-MTBC genomes) places the gene on the ancient-core ↔ MTBC-specific axis: a gene absent even from the closest MTBAP relatives is a candidate MTBC-specific innovation (possible host-adaptation factor, to confirm by synteny). The phylostratum extends that axis outside the genus (tblastn vs 13 reference genomes spanning Mycobacteriaceae → Corynebacteriales → Actinomycetia → outside the phylum): it is the deepest clade in which a homolog is still detected, i.e. a proxy for gene age. Read it with the null model in mind: a shallow (young) stratum can also reflect homology-detection failure for short or fast-evolving ORFs, so it is a descriptive axis, not a proof of novelty.

Essentiality (transposon mutagenesis) essential

DeJesus 2017 callES · essential
What the call meansessential: insertions absent across the whole ORF
TA sites (Himar1) 16 in the ORF — 15 in the essential state, 0 growth-defect, 1 non-essential, 0 growth-advantage. Saturation 0.062, mean read count 8. A region of the protein devoid of TA sites is invisible to this assay: nothing can be inferred about it, in either direction.
All 16 sites lie in this ORF alone (no overlapping CDS shares any), so the call is attributable to this gene.

Genome-wide Himar1 transposon essentiality in H37Rv (DeJesus 2017). An essential call (ES/ESD/GD) is strong, independent evidence that a "hypothetical" locus encodes a functional, selectively required gene — orthogonal to intra-species conservation.

Chemical-genetic target & druggability (PROSPECT) hypomorph tool strain validated drug target

This gene is part of the PROSPECT collection of TetON transcriptional-knockdown (hypomorph) strains of essential M. tuberculosis genes, built as a sensitised background for chemical-genetic mechanism-of-action deconvolution. Being in the panel means the gene is an essential / vulnerable target for which a validated knockdown tool strain exists.

Hypomorph strainkasA-TetOn 18.1 (TetON promoter 18)
Baseline knockdown fitness4.52 median doublings (across 6 screen pool(s)) — fewer doublings = stronger growth defect on knockdown
Used in target deconvolutionyes (informs phenotypic-cluster / MOA assignment)
Drug-target cross-referenceannotated mechanism-of-action target KasA: 2 reference compound(s) phenocopy its inhibition — chemically-validated druggable target

Panel membership reflects essentiality/vulnerability and the availability of a genetic tool, not a specific molecular function; it never changes the verdict here. Source: Bond AN et al., Nat Commun 2025;16:9673 (doi:10.1038/s41467-025-64662-x); PROSPECT chemical-genetic platform.

Proteomics (mass spectrometry) detected

MS detectiondetected in 16 of 16 independent MS datasets
Integrated abundance1812.0 ppm · rank 99/3519 (97.2th percentile)

Detection by mass spectrometry is direct, experimental evidence that the protein product exists — orthogonal to sequence conservation and to Tn-seq essentiality, and especially decisive for a "hypothetical" locus. Read the dataset count as abundance, not as replication. Measured across this atlas (3,491 detected proteins), the number of datasets a protein appears in tracks its abundance almost monotonically: median 1.2 ppm at 1 dataset of 16, 27 ppm at 10, 392 ppm at 15, 1,325 ppm at 16 — three orders of magnitude. A high count therefore says the protein is abundant more than it says several independent experiments confirmed it. What the count does establish, at any value, is that the product exists.

Predicted localisation (DeepTMHMM + lipobox) no export signal, no TM helix

Predictionno signal peptide, no TM helix (DeepTMHMM class GLOB)
DeepTMHMM classGLOB

A verified absence of signals, which is not a compartment. No Sec/Tat signal peptide, no transmembrane helix and no lipobox were found on this sequence. The predictor reports topology and export signals; it does not measure where the protein ends up, so this page draws no cytoplasmic conclusion from it. In M. tuberculosis that reservation is not theoretical: the 12 Esx paralogues of this atlas — EsxA/ESAT-6 and EsxB/CFP-10 among them, the best-established secreted proteins of the species — carry this very call, because substrates of the type VII (ESX) secretion system leave no recognisable signal. « Secreted » and « no signal peptide » are true together here.

Transmembrane topology and signal peptide from DeepTMHMM (deep-learning reference predictor); lipoproteins from a (myco)bacterial lipobox motif. A sequence-based prediction of subcellular context.

Physico-chemical properties (computed, ProtParam)

Length416 aa
Molecular weight43.3 kDa
Theoretical pI5.11
GRAVY0.03 (hydrophobic)
Aliphatic index86.2
Aromaticity0.055
Instability index35.3 (stable)

Computed from the ancestral MTBC0 sequence with the ExPASy ProtParam method (Biopython). Descriptive biophysical context: a positive GRAVY flags a hydrophobic (often membrane) protein, a high instability index (>40) predicts a short in-vitro half-life, an extreme pI hints at compartment or binding partner.

Domains (Pfam, hmmscan --cut_ga)

PfamAccessioni-EvalueResiduesDescription
ketoacyl-syntPF00109.33 1.1e-4913–252 Beta-ketoacyl synthase, N-terminal domain
Thiolase_NPF00108.30 9.8e-07152–199 Thiolase, N-terminal domain
Ketoacyl-synt_CPF02801.29 9.5e-32262–374 Beta-ketoacyl synthase, C-terminal domain

3D structure (interactive — Mol*/pdbe-molstar)

Experimental structure 6y2i (PDBe), the strongest available structural evidence for this gene. Drag to rotate, scroll to zoom; hetero-groups (ligands, ions, waters hidden by default) shown as sticks.

Experimental structures (Protein Data Bank) 14 solved

PDBMethodResolutionCoverage
6y2i X-ray diffraction 1.533 Å 100%
2wge X-ray diffraction 1.8 Å 100%
5w2o X-ray diffraction 1.8 Å 100%
5w2q X-ray diffraction 1.8 Å 100%
2wgg X-ray diffraction 2.0 Å 100%
5w2p X-ray diffraction 2.0 Å 100%
2wgd X-ray diffraction 2.01 Å 100%
5ld8 X-ray diffraction 2.13 Å 100%

Experimentally solved structures mapped from the UniProt accession via PDBe/SIFTS (14 total; up to 8 shown, ranked by sequence coverage then resolution). An experimental structure is direct proof of the folded product and the strongest structural evidence — superseding the predicted ESMFold/AlphaFold models below for any covered region.

Structural search (AlphaFold DB model, Foldseek vs PDB — genome-wide) pLDDT 98.5

PDB hitprobTM (aln)TM (query)TM (target)Seq. id.Cov. q / tE-valueDescription
2wgg-assembly1_A 1.00 1.00 1.00 1.00 100% 100% / 100% 1.2e-91 sig 2wgg-assembly1_A Crystal Structure of Mycobacterium tuberculosis C171Q KasA variant with bound TLM
4c6v-assembly1_A 1.00 1.00 0.99 1.00 100% 100% / 100% 1.3e-89 sig 4c6v-assembly1_A Crystal structure of M. tuberculosis KasA in complex with TLM5 (Soak for 5 min)
2gp6-assembly1_B 1.00 0.97 0.95 0.95 66% 98% / 98% 3.4e-66 sig 2gp6-assembly1_B X-ray crystal structure of Mycobacterium tuberculosis beta-ketoacyl acyl carrier protein synthase II (mtKasB)
1j3n-assembly1_A 1.00 0.95 0.93 0.95 41% 97% / 100% 8.1e-50 sig 1j3n-assembly1_A Crystal Structure of 3-oxoacyl-(acyl-carrier protein) Synthase II from Thermus thermophilus HB8
4r8e-assembly1_B 1.00 0.94 0.93 0.94 42% 97% / 100% 2.2e-50 sig 4r8e-assembly1_B Crystal structure of beta-ketoacyl-ACP synthase II (FabF) from Yersinia pestis

Foldseek search of the AlphaFold DB model (mean pLDDT 98.5, gated at 70) against the PDB — a genome-wide extension of the ESMFold dark-gene search that also covers proteins beyond the single-sequence length limit. Confident structural neighbours (E < 0.01) shown.

Genomic context (neighbours & predicted operon) operon of 4

Upstream (5' on genome)acpM (+ strand, -4 bp gap)
Downstream (3' on genome)kasB (+ strand, 30 bp gap)
Predicted operon acpM · kasA · kasB · accD6

Neighbours from the H37Rv annotation (+ strand). The operon is predicted by co-directional intergenic distance (same strand, gaps ≤50 bp) — a transcription-unit hypothesis, not a mapped TSS. For a "hypothetical", co-transcription with a characterised operon is a concrete functional lead (complements the STRING neighborhood channel below).

Published operon evidence (two independent sources)

Roback 2007 (logistic regression: distance + expression correlation, 474 microarrays) operon of 6: fabD · mcr16 · acpM · kasA · kasB · accD6 — disagrees with the distance heuristic above
REMap 2016 (RNA-seq coverage continuity, CDC1551, tag MT2305) exponential phase: operon of 6, Rv2243 · Rv2244 · Rv2245 · Rv2246 · Rv2247 · Rv2248 (coverage 122.04)
stationary phase: operon of 5, Rv2243 · Rv2244 · Rv2245 · Rv2246 · Rv2247 (coverage 150.56) — disagrees with the distance heuristic above

Two independent published operon maps, cited alongside the distance heuristic above: an association corroborating or contradicting the heuristic, never proof of shared function. REMap's RNA-seq coverage continuity is the most direct of the three signals; Roback's logistic regression and the intergenic-distance heuristic are statistical proxies.

Transcriptional regulation (signed TRN: ChIP-seq + TFOE)

Regulated by (1 TF) trcR (represses)

Regulatory edges from the ISB signed transcriptional regulatory network (TF ChIP-seq binding, Minch 2015 + TF-overexpression response, Rustad 2014). An edge is regulatory evidence (binding and/or expression change), not necessarily direct. For a "hypothetical", membership in a known regulon (e.g. DosR dormancy, PhoP virulence) is a physiological-context lead, not a function.

Condition: Condition-blind by construction. These edges come from transcription-factor OVEREXPRESSION in a single laboratory condition, so a listed regulator is not a claim that it governs this gene in every circumstance. Measured counter-examples exist within this atlas (see Rv2516c, where the DosR regulon collapses under moxifloxacin while the gene itself rises). Read a regulator as 'capable of shifting this gene', and look for the condition before building a hypothesis on it.

Additional regulons (curated, outside the TFOE-derived TRN)

crp binding site only -- direction not determined (low confidence · CRP regulon (Kahramanoglou et al. 2014))
ChIP-seq : site de fixation CRP (1 des 191 sites de Kahramanoglou et al. 2014) ; aucun changement d'expression rapporte pour ce gene chez le mutant delta-crp
Caveat: Site de fixation CRP mesure par ChIP-seq (Kahramanoglou et al. 2014), SANS changement d'expression mesure pour ce gene chez le mutant delta-crp : le sens de la regulation n'est PAS determine. Ecrire « site de fixation CRP en amont », jamais « regule par CRP ». L'article ne distingue pas « non differentiellement exprime » de « sous le seuil », donc l'absence de ce gene de la table d'expression n'est pas une preuve de non-regulation.

Curated from primary literature not covered by the ISB signed TRN (Minch 2015 / Rustad 2014): Zur regulon (Maciag et al. 2007, PMID 17098899), SigG regulon (Gaudion et al. 2013, PMID 23871545), LexA/SOS regulon (Smollett et al. 2012, PMID 22528497) — added P16.25 (2026-08-18); CRP regulon (Kahramanoglou et al. 2014, PMID 24957601) — added P16.25b (2026-09-27). Confidence and caveats are per-edge and carried from the source paper — read them before citing a specific gene as "regulated by" its listed TF. An entry reading "binding site only — direction not determined" is not a regulation claim: it records a measured ChIP-seq binding site for which the source reports no expression change, and the absence of such a change is not evidence of absent regulation.

Functional interaction network (STRING v12, guilt-by-association)

Explore full network →

Node colour = verdict, dashed = still uncharacterised; edge colour = evidence (green experimental, orange genomic-context, grey co-expression), width ∝ score. Click a partner to open its page; "Explore full network" to walk the graph.

Closest characterised functional partner: fabD (malonyl CoA-acyl carrier protein transacylase), high confidence (score 997, all STRING channels except text-mining; the partner is chosen on its genomic-context evidence).

Showing the 15 strongest of this gene's 138 partners at medium confidence (29 at high confidence). The table is an extract, not a neighbourhood: across the proteome the real median degree is 34 while the served median is 15, so no hub, degree distribution or centrality may be read on this table. None of the 138 partners rests on an interaction measured in M. tuberculosis itself.

PartnerProductScoreNo text-miningChannels (≥400)
Rv2243 fabD malonyl CoA-acyl carrier protein transacylase 999 997 ctx neighborhood:788 cooccurence:769 coexpression:934 textmining:947
Rv2244 acpM exp (transferred) meromycolate extension acyl carrier protein 999 989 ctx neighborhood:882 coexpression:810 experimental:408 textmining:946
Rv2246 kasB paralog 3-oxoacyl-ACP synthase 2 977 977 ctx neighborhood:836 coexpression:860
Rv0904c accD3 acetyl-CoAcarboxylase carboxyl transferase subunit beta 983 976 coexpression:961
Rv2247 accD6 acetyl-/propionyl-CoA carboxylase subunit beta 997 971 ctx neighborhood:798 coexpression:860 textmining:914
Rv0533c fabH 3-oxoacyl-ACP synthase III 988 922 ctx cooccurence:750 coexpression:678 textmining:860
Rv2933 ppsC exp (transferred) paralog phthiocerol synthesis polyketide synthase type I PpsC 929 899 coexpression:485 experimental:785
Rv1527c pks5 exp (transferred) paralog polyketide synthase 928 899 coexpression:488 experimental:785
Rv3825c pks2 exp (transferred) paralog phthioceranic/hydroxyphthioceranic acid synthase 928 899 coexpression:485 experimental:785
Rv2048c pks12 exp (transferred) paralog polyketide synthase 926 899 coexpression:488 experimental:785
Rv2940c mas exp (transferred) paralog multifunctional mycocerosic acid synthase 926 899 coexpression:490 experimental:785
Rv1663 pks17 exp (transferred) polyketide synthase 889 882 coexpression:443 experimental:785
Rv1484 inhA NADH-dependent enoyl-[ACP 994 836 ctx cooccurence:466 coexpression:688 textmining:965
Rv3285 accA3 bifunctional protein acetyl-/propionyl-CoA carboxylase subunit alpha AccA 854 808 ctx cooccurence:654 coexpression:449
Rv1483 fabG1 3-oxoacyl-ACP reductase FabG 947 792 ctx cooccurence:655 textmining:759

STRING combines evidence channels (neighborhood, fusion, cooccurrence, coexpression, experimental, database, text-mining) into a 0–1000 score. The ctx badge marks edges carried by the genomic-context channels (conserved neighborhood, fusion, phylogenetic co-occurrence), which are independent of orthology and structure and the strongest signal for an unknown gene. The no text-mining column recomputes the score from data alone, so a link that does not depend on the literature is visible. Association is a function hypothesis, not proof: corroborate with the operon context and the primary literature before assigning a function.

Where the experimental evidence comes from, and why it matters here. STRING's experimental channel fuses interactions measured in M. tuberculosis with interactions measured in another organism and transferred to this pair by orthology. The two are not equivalent for this atlas, whose standing rule is that better studied elsewhere is not a function established in M. tuberculosis. Measured on the served network: of the 38 229 partner pairs shown across the atlas, 13 483 partner rows carry a non-zero experimental channel, and only 106 pairs rest on an interaction measured in M. tuberculosis itself — 0.3 % of the network. Those 106 are long-established complexes (ESX-1/ESAT-6, RNA polymerase with CarD and RbpA, the Pup–Mpa proteasome, gyrase, Emb, GarA with PknB and PknG, the Rel modules); no still-uncharacterised gene is among them. The reason is not a gap in this atlas but in the literature: there is almost no experimental interactome of this bacterium, IntAct holding 134 curated protein pairs for a ~4 000-gene proteome. A exp (transferred) badge is therefore a lead, never a measurement, and an absence of badge is not evidence that the pair does not interact.

Evidence

  • Legacy H37Rv annotation: 3-oxoacyl-ACP synthase 1
  • MTBC0 PGAP product: 3-oxoacyl-ACP synthase KasA
  • Pfam (hmmscan --cut_ga): ketoacyl-synt PF00109.33 (E=1e-49), Thiolase_N PF00108.30 (E=1e-06), Ketoacyl-synt_C PF02801.29 (E=9e-32)
  • (auto-curated by rules from PGAP + Pfam + Foldseek; not hand-reviewed)

Sources

  • Ancestral sequence & coordinates: Harrison LB et al. (2024), An imputed ancestral reference genome for the MTBC, doi:10.1101/2023.09.07.556366
  • Product annotation: NCBI PGAP on MTBC0; legacy from H37Rv NC_000962.3 (RefSeq NP_216761.1)
  • Domains: Pfam-A via hmmscan --cut_ga — ketoacyl-synt (PF00109.33), Thiolase_N (PF00108.30), Ketoacyl-synt_C (PF02801.29)
  • Sequence-level signal: ESM Atlas (EvolutionaryScale × BioHub) — exploratory
  • Controlled vocabulary: eggNOG-mapper 2.1.12 (Cantalapiedra et al. 2021, doi:10.1093/molbev/msab293), eggNOG 5.0 DB (Huerta-Cepas et al. 2019) — OG COG0304
  • Curated reference: UniProt P9WQD9 (SwissProt, reviewed; Evidence at protein level)
  • Intra-MTBC selection: pN/pS and disruption from SPDI variants of 142 601 MTBC strains (this work, local collection vs H37Rv NC_000962.3)
  • Genome-wide structure: AlphaFold DB model (Jumper et al. 2021, doi:10.1038/s41586-021-03819-2; Varadi et al. 2024, doi:10.1093/nar/gkad1011) searched vs PDB with Foldseek (mean pLDDT 98.5)
  • Interaction network: STRING v12.0 (Szklarczyk et al. 2023, doi:10.1093/nar/gkac1000), taxon 83332, CC-BY 4.0 — 138 functional partner(s); context anchor fabD
  • Essentiality: genome-wide transposon mutagenesis in H37Rv — DeJesus et al. 2017 (mBio, doi:10.1128/mBio.02133-16, CC BY)
  • Proteomics: integrated mass-spectrometry abundance from PaxDb 5.0 (Huang et al. 2023, doi:10.1016/j.mcpro.2023.100640), taxon 83332 — weighted average of 16 datasets, incl. Schubert et al. 2013 (doi:10.1016/j.chom.2013.04.008) and Albrethsen et al. 2013 (doi:10.1074/mcp.M112.018846)
  • Functional category: TubercuList scheme (Cole et al. 1998, doi:10.1038/31159), via Mycobrowser (Kapopoulou et al. 2011, doi:10.1016/j.tube.2010.09.006)
  • Orthologues: reciprocal best hits (DIAMOND, Buchfink et al. 2021, doi:10.1038/s41592-021-01101-x) against Mycobrowser release 5 reference proteomes
  • Experimental structures: PDBe/SIFTS UniProt→PDB mapping (Dana et al. 2019, doi:10.1093/nar/gky1114)
  • Genomic context / operon: H37Rv annotation; operon predicted by co-directional intergenic distance (Salgado et al. 2000, doi:10.1073/pnas.030539397)
  • Transcriptional regulation: ISB signed TRN — TF ChIP-seq (Minch et al. 2015, doi:10.1038/ncomms6829) + TF overexpression (Rustad et al. 2014, doi:10.1186/gb-2014-15-11-502)
  • Physico-chemical properties: ExPASy ProtParam method via Biopython (Gasteiger et al. 2005), computed from the MTBC0 sequence
  • Predicted localisation: DeepTMHMM (Hallgren et al. 2022, doi:10.1101/2022.04.08.487609) for transmembrane topology and signal peptide
  • Primary literature: none located yet; annotation rests on the domain/homology sources above.

Ancestral MTBC0 protein sequence

>mtbc0_002387|Rv2245|kasA
MSQPSTANGGFPSVVVTAVTATTSISPDIESTWKGLLAGESGIHALEDEFVTKWDLAVKIGGHLKDPVDSHMGRLDMRRMSYVQRMGKLLGGQLWESAGSPEVDPDRFAVVVGTGLGGAERIVESYDLMNAGGPRKVSPLAVQMIMPNGAAAVIGLQLGARAGVMTPVSACSSGSEAIAHAWRQIVMGDADVAVCGGVEGPIEALPIAAFSMMRAMSTRNDEPERASRPFDKDRDGFVFGEAGALMLIETEEHAKARGAKPLARLLGAGITSDAFHMVAPAADGVRAGRAMTRSLELAGLSPADIDHVNAHGTATPIGDAAEANAIRVAGCDQAAVYAPKSALGHSIGAVGALESVLTVLTLRDGVIPPTLNYETPDPEIDLDVVAGEPRYGDYRYAVNNSFGFGGHNVALAFGRY